SIGA Technologies, Inc. - 10-K Summary (Fiscal Year Ended Dec 31, 2004)
Business Context and Reporting Period
SIGA Technologies, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel anti-infectives, antibiotics, and vaccines for serious infectious diseases and biological warfare agents (e.g., Smallpox, Arenaviruses). The company operates as a single reporting unit with headquarters in New York and research facilities in Corvallis, Oregon. As of December 31, 2004, SIGA had no commercial products and remains in the pre-revenue stage regarding product sales, relying on government grants and collaborative agreements for funding.
Key Financial Metrics
| Metric (in thousands) | 2004 | 2003 |
|---|---|---|
| Revenues | $1,839 | $732 |
| Operating Loss | $(9,448) | $(5,295) |
| Net Loss | $(9,373) | $(5,277) |
| Net Loss Per Share (Basic/Diluted) | $(0.40) | $(0.34) |
| Cash and Cash Equivalents (Year End) | $2,021 | $1,441 |
| Net Cash Used in Operating Activities | $(4,890) | $(5,332) |
| Total Assets | $6,111 | $6,100 |
| Accumulated Deficit | $(44,181) | $(34,808) |
Debt and Liquidity: The company reported no long-term debt. Total liabilities were $1.55 million, primarily consisting of accounts payable and accrued expenses. Management believes cash on hand ($2.02 million) and projected cash flows are sufficient to support operations beyond December 31, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 151% to $1.84 million, driven primarily by the award of two Phase I and two Phase II SBIR grants from the NIH totaling approximately $12.1 million in Q3 2004. Revenue from the U.S. Army contract also increased by 35%.
- Expense Increases: Operating expenses rose significantly. Selling, general, and administrative (SG&A) expenses increased 53% due to higher payroll (new CEO and VP hires) and a 272% increase in legal fees related to Sarbanes-Oxley compliance and corporate governance. Research and development (R&D) expenses increased 42% due to staff expansion and amortization of acquired assets.
- Non-Cash Charges: The company recorded a $2.12 million non-cash impairment of intangible assets (primarily technology acquired from Plexus) and $568,000 in in-process research and development (IPRD) expenses related to the ViroPharma acquisition.
- Acquisitions: In August 2004, SIGA acquired Smallpox and Arenavirus antiviral programs and associated government grants from ViroPharma for $1 million cash and 1 million shares of common stock.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring operating losses for the foreseeable future. The company anticipates needing additional funds to complete product development. While current resources are projected to last beyond December 31, 2005, there is no assurance that additional financing will be available on acceptable terms.
Key Risks:
- Dependence on Grants: Future revenues are heavily contingent on government grants (NIH and U.S. Army) and collaborative agreements. Substantially all revenue in 2004 was derived from these sources.
- Development Risk: All product candidates are in early stages. There is a high risk of failure in pre-clinical or clinical trials, and no assurance of regulatory approval or commercial viability.
- Liquidity: Continued losses and negative cash flow require ongoing equity or debt financing. Failure to raise capital could force the discontinuation of operations.
- Intellectual Property: Success depends on maintaining patent protection and avoiding infringement claims, which are common in the biotechnology sector.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.02 million cash balance against the projected burn rate to confirm operations can continue beyond late 2005 without dilutive financing.
- Grant Sustainability: Assess the renewal status and funding certainty of the NIH SBIR grants ($12.1 million total award) and the U.S. Army contract, which constitute the majority of revenue.
- Asset Impairment: Review the rationale for the $2.12 million impairment charge on Plexus technology to understand the strategic shift toward Smallpox/Arenavirus programs.
- Related Party Transactions: Examine the $10 million investment from MacAndrews & Forbes and TransTech Pharma, noting the related-party nature and the significant ownership concentration (approx. 48% by insiders).
- Regulatory Pathway: Confirm the specific FDA regulatory requirements for the Smallpox antiviral (animal efficacy data) versus the Strep vaccine (human clinical trials) and the associated timelines.